


K02288

Cat. No.:	HY-12278		
CAS No.:	1431985-92-0		
Molecular Formula:	C ₂₀ H ₂₀ N ₂ O ₄		
Molecular Weight:	352.38		
Target:	TGF-β Receptor		
Pathway:	TGF-beta/Smad		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 58.6 mg/mL (166.30 mM)
 * "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
	1 mM	2.8378 mL	14.1892 mL	28.3785 mL
	5 mM	0.5676 mL	2.8378 mL	5.6757 mL
	10 mM	0.2838 mL	1.4189 mL	2.8378 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
 Solubility: ≥ 2.5 mg/mL (7.09 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
 Solubility: ≥ 2.5 mg/mL (7.09 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil
 Solubility: ≥ 2.5 mg/mL (7.09 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

K02288 is a potent bone morphogenetic protein (BMP) type I receptor inhibitor with IC₅₀s of 1.8, 1.1, 6.4 nM for ALK1, ALK2 and ALK6, respectively. K02288 shows slightly weaker inhibition against ALK3 and ALK6 with IC₅₀s of 5-34 nM.

IC₅₀ & Target

IC₅₀ 1.8 nM (ALK1), 1.1 nM (ALK2), 34.4 nM (ALK3), 6.3 nM (ALK6), 302 nM (ALK4), 321 nM (ALK5)^[1]

In Vitro

K02288 reduces a robust phosphorylation of Smad1/5/8 induced by BMP4 stimulation, with an apparent IC₅₀ of 100 nM.

K02288 causes near complete inhibition of Smad2 phosphorylation at 0.5 μM ^[1]. K02288 binds to ALK1 in an ATP-mimetic fashion with two hydrogen bonds to the kinase hinge. K02288 also inhibits BMP9-ALK1 signalling, and induces a hypersprouting phenotype in HUVECs^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

K02288 (1 μM) induces dysfunctional angiogenesis in a chick embryo CAM model^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Exp Mol Med. 2022 Oct 12.
- Bioorg Med Chem Lett. 2020 Dec 1;30(23):127608.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Sanvitale CE, et al. A new class of small molecule inhibitor of BMP signaling. PLoS One. 2013 Apr 30;8(4):e62721.

[2]. Kerr G, et al. A small molecule targeting ALK1 prevents Notch cooperativity and inhibits functional angiogenesis. Angiogenesis. 2015 Apr;18(2):209-17.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA